Gulnaz Iqbal

Coventry, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Translation and interpreting services must be considered across the lifecycle of clinical trials.

Translation and interpreting services must be considered across the lifecycle of clinical trials.

Journal: Trials

Published: November 08, 2025

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.

Journal: British journal of haematology

Published: August 08, 2025

Exploring the effect of differing centre hydration and anti-emetic policies on acute gastrointestinal and renal toxicities in the De-ESCALaTE trial.

Exploring the effect of differing centre hydration and anti-emetic policies on acute gastrointestinal and renal toxicities in the De-ESCALaTE trial.

Journal: BJC reports

Published: August 08, 2024

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.

Journal: Cancers

Published: February 28, 2023

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Journal: Blood cancer journal

Published: July 28, 2022

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.

Journal: Blood advances

Published: April 01, 2022

Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials.

Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 09, 2022

Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study.

Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: April 08, 2021

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Journal: Blood cancer journal

Published: June 09, 2020

Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.

Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.

Journal: British journal of haematology

Published: May 14, 2020

Levofloxacin prophylaxis in patients with myeloma - Authors' reply.

Levofloxacin prophylaxis in patients with myeloma - Authors' reply.

Journal: The Lancet. Oncology

Published: January 10, 2020

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.

Journal: Health technology assessment (Winchester, England)

Published: November 07, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026